Next Article in Journal
Exploiting Mitochondrial Vulnerabilities to Trigger Apoptosis Selectively in Cancer Cells
Previous Article in Journal
Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer
Previous Article in Special Issue
Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia
Article Menu

Export Article

Open AccessReview

Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application

1
Department of Oncology-Pathology, Karolinska Institutet, 171 76 Stockholm, Sweden
2
Department of Hematology, Karolinska University Hospital, 171 76 Stockholm, Sweden
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(7), 915; https://doi.org/10.3390/cancers11070915
Received: 28 May 2019 / Revised: 21 June 2019 / Accepted: 25 June 2019 / Published: 29 June 2019
(This article belongs to the Special Issue Signaling Pathways and Immune Checkpoint Regulation in Cancer)
  |  
PDF [1231 KB, uploaded 3 July 2019]
  |  

Abstract

In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor microenvironment (TME). The features of the TME differ between the different lymphoma types, ranging from extremely inflammatory, such as in Hodgkin lymphoma, to anergic, leading to immune deficiency and susceptibility to infections, such as in chronic lymphocytic leukemia. Understanding the characteristic features of the TME as well as the interactions between cancer and TME cells has given insight into the pathogenesis of most lymphomas and contributed to identify novel therapeutic targets. Here, we summarize the preclinical data that contributed to clarifying the role of the immune cells in the TME of different types of lymphomas of B-cell origin, and explain how the understanding of the biological background has led to new clinical applications. Moreover, we provide an overview of the clinical results of trials that assessed the safety and efficacy of drugs directly targeting TME immune cells in lymphoma patients. View Full-Text
Keywords: B-cell lymphoma; tumor microenvironment; immune cells; T cells; PD-1; PD-L1; macrophages; CD47; Hodgkin lymphoma B-cell lymphoma; tumor microenvironment; immune cells; T cells; PD-1; PD-L1; macrophages; CD47; Hodgkin lymphoma
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Mulder, T.A.; Wahlin, B.E.; Österborg, A.; Palma, M. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. Cancers 2019, 11, 915.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top